1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Cardio3 and Cellular Dynamics join IPO hopefuls

 
• By Madeleine Armstrong

Two stem cell specialists will soon become the latest to take their chances on the public markets: Cardio3 Biosciences and Cellular Dynamics have both announced plans for initial public offerings (IPOs).

Two stem cell specialists will soon become the latest to take their chances on the public markets: Cardio3 Biosciences and Cellular Dynamics have both announced plans for initial public offerings (IPOs).

Cellular Dynamics (based in Madison, Wisconsin) is hoping to raise up to $57.3m in its IPO on Nasdaq. The company,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Why India Revoked The Entresto Patent And Novartis Abstained From Proceedings

 
• By Anju Ghangurde

India revokes Novartis's patent pertaining to Entresto, upholding the objections of opponents including the Indian Pharmaceutical Alliance on lack of novelty and prior claiming, among others. Novartis decided against participating in the hearings.

Stock Watch: Pfizer’s Vyndaqel Withdrawal

 
• By Andy Smith

The removal of a lower-dose version of a drug with years of patent-protected sales remaining in favor of a higher dose, lower-pill count version was billed as a convenience enhancement for patients. Payers, however, do not reimburse convenience.

September Deals Freshen Up Novartis’s Cardio Franchise

 
• By Kevin Grogan

As its biggest seller Entresto succumbs to generic competition.

Novartis Buys Tourmaline Bio, Setting Up Showdown With Novo Nordisk

 
• By Manas Mishra

Novartis is acquiring Tourmaline Bio for $1.4bn to gain pacibekitug, a promising IL-6 inhibitor for cardiovascular disease, setting up a direct rivalry with Novo Nordisk’s ziltivekimab.

More from Therapeutic Category

Roche’s evERA Giredestrant Study Hits In All-Comer Breast Cancer Population

 
• By Alexandra Shimmings

The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.

Sanofi’s Pipeline Pressure Continues As Tolebrutinib Trips Near Finish Line

 
• By Manas Mishra

Sanofi’s MS hopeful tolebrutinib hits a regulatory hurdle in the US, renewing pressure on the firm’s pipeline. Analysts hope the delay won’t prove material.

Why India Revoked The Entresto Patent And Novartis Abstained From Proceedings

 
• By Anju Ghangurde

India revokes Novartis's patent pertaining to Entresto, upholding the objections of opponents including the Indian Pharmaceutical Alliance on lack of novelty and prior claiming, among others. Novartis decided against participating in the hearings.